- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04981587
Effects of Strength Exercise on Fall Risk in Elderly With Alzheimer's Disease
March 4, 2022 updated by: Alexander Achalandabaso, University of Jaén
Interventional study to show the effects of strength exercise on fall risk in elderly with Alzheimer's disease
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
64
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Andalucía
-
Jaén, Andalucía, Spain
- A.F.A La Estrella
-
-
Madrid
-
Alcalá De Henares, Madrid, Spain, 28805
- Alexander achalandabaso
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
60 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- accept to participate in the study, through informed consent
- subjects aged 60 or over with medical diagnosis of Azlheimer´s disease
- minimal physical and mental state to perform the cognitive tests and strength exercise routine
Exclusion Criteria:
- Neurodegenerative disease other than Alzheimer's disease
- Suffering from serious somatic or psychiatric illnesses
- Patients who have practiced strength exercise regularly
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Intervention group
This is the group that receives strength exercise in addition to usual treatment
|
Strength exercise protocol for upper and lower limbs, using weights and elastic bands
The usual treatment is based on activities to enhance brain functions: attention, memory, executive functions, language and orientation.
|
|
Other: Control group
This is the group that only receives usual treatment
|
The usual treatment is based on activities to enhance brain functions: attention, memory, executive functions, language and orientation.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change from baseline Short physical performance battery (SPPB) at 3 and 6 months
Time Frame: Baseline, 3 and 6 months (3 months after intervention)
|
Informs about fall risk and mobility Score: 0-12 High score means better result
|
Baseline, 3 and 6 months (3 months after intervention)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change from baseline Activities specific balance confidence scale (ABC scale) at 3 and 6 months
Time Frame: Baseline, 3 and 6 months (3 months after intervention)
|
This questionnaire allows to measure the balance of a person Score: 0-100% High percentage means better result
|
Baseline, 3 and 6 months (3 months after intervention)
|
|
Change from baseline Lawton Instrumental Activities of Daily Living Scale (IADL) at 3 and 6 months
Time Frame: Baseline, 3 and 6 months (3 months after intervention)
|
This tool gives us information about performance in activities of daily living Score: 0-8 High score means better result
|
Baseline, 3 and 6 months (3 months after intervention)
|
|
Change from baseline Quality of life Alzheimer Disease (QoL-AD) at 3 and 6 months
Time Frame: Baseline, 3 and 6 months (3 months after intervention)
|
Through this test we can know the level of quality of life of users who suffer from this disease Score: 0-52 High score means better result
|
Baseline, 3 and 6 months (3 months after intervention)
|
|
Change from baseline FRAIL test at 3 and 6 months
Time Frame: Baseline, 3 and 6 months (3 months after intervention)
|
This rapid test allows to determine the state of frailty of older people Score: 0-5 High score means worst result
|
Baseline, 3 and 6 months (3 months after intervention)
|
|
Change from baseline Mini Mental State Examination (MMSE) at 3 and 6 months
Time Frame: Baseline, 3 and 6 months (3 months after intervention)
|
This test gives us information about the cognitive performance of the participants Score: 0-30 High score means better result
|
Baseline, 3 and 6 months (3 months after intervention)
|
|
Change from baseline Neuropsychiatric Inventory (NPI-Q) at 3 and 6 months
Time Frame: Baseline, 3 and 6 months (3 months after intervention)
|
This tool allows to specify the neuropsychiatric symptoms patients present Score: 0-36 High score means worst result
|
Baseline, 3 and 6 months (3 months after intervention)
|
|
Change from baseline Manual dynamometry at 1,2,3 and 6 months
Time Frame: Baseline, 1, 2, 3 and 6 months (3 months after intervention)
|
This test allows to quantify force an individual presents in a simple way Score: 0-∞ High score means better result
|
Baseline, 1, 2, 3 and 6 months (3 months after intervention)
|
|
Modified Borg scale
Time Frame: 3 times/week during strength exercises sessions
|
In this way we can measure the level of perceived exertion during the intervention with strength exercise Score: 0-10 High score means more fatigue
|
3 times/week during strength exercises sessions
|
|
Change from baseline One Maximum repetition strength test (1 MR) at 1,2,3 and 6 months
Time Frame: Baseline, 1 , 2 , 3 and 6 months (3 months after intervention)
|
Allows you easily to assess maximum strength Score: 0-∞ High score means more strength level
|
Baseline, 1 , 2 , 3 and 6 months (3 months after intervention)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 1, 2021
Primary Completion (Actual)
December 10, 2021
Study Completion (Actual)
March 4, 2022
Study Registration Dates
First Submitted
July 19, 2021
First Submitted That Met QC Criteria
July 28, 2021
First Posted (Actual)
July 29, 2021
Study Record Updates
Last Update Posted (Actual)
March 7, 2022
Last Update Submitted That Met QC Criteria
March 4, 2022
Last Verified
March 1, 2022
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CEIH/FEB.21/8.TES
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alzheimer Disease
-
ProgenaBiomeWithdrawnAlzheimer Disease | Alzheimer Disease, Early Onset | Alzheimer Disease, Late Onset | Alzheimer Disease 1 | Alzheimer Disease 2 | Alzheimer Disease 3 | Alzheimer Disease 4 | Alzheimer Disease 7 | Alzheimer Disease 17 | Alzheimer Disease 5 | Alzheimer Disease 6 | Alzheimer Disease 8 | Alzheimer Disease 10 | Alzheimer... and other conditionsUnited States
-
Cognito Therapeutics, Inc.Active, not recruitingCognitive Impairment | Dementia | Alzheimer Disease | Mild Cognitive Impairment | Cognitive Decline | Alzheimer Disease, Early Onset | Alzheimer Disease, Late Onset | MCI | Dementia Alzheimers | Mild Dementia | Dementia of Alzheimer Type | Cognitive Impairment, Mild | Alzheimer Disease 1 | Dementia, Mild | Alzheimer... and other conditionsUnited States
-
Stanford UniversityNot yet recruitingMCI With Increased Risk for Alzheimer Disease | Alzheimer s DiseaseUnited States
-
University of California, Los AngelesRecruitingAlzheimer Disease | Dementia Alzheimer Type | Alzheimer&Amp;#39;s Disease (AD) | Alzheimer&Amp;Amp;#39;s Disease | Mild Alzheimer&Amp;Amp;#39;s Disease | Moderate Alzheimer&Amp;Amp;#39;s Disease | Alzheimer&Amp;#39;s DementiaUnited States
-
AphiosNot yet recruitingDementia | Alzheimer Disease 1 | Alzheimer Disease 2 | Alzheimer Disease 3
-
Heinrich-Heine University, DuesseldorfNot yet recruitingEarly Onset Alzheimer Disease | Alzheimer Disease (AD)Germany
-
University Hospital, GrenobleRecruiting
-
Fujian Medical University Union HospitalRecruitingAlzheimer s DiseaseChina
-
AkesoNot yet recruitingAlzheimer' s DiseaseChina
-
Johns Hopkins UniversityNational Institutes of Health (NIH)Not yet recruiting
Clinical Trials on Strength exercise
-
University of British ColumbiaCanadian Institutes of Health Research (CIHR)CompletedDiabetic | CardiovascularCanada
-
Basque Health ServiceUnknown
-
SwanenburgTerminatedChronic Disease | Joint Instability | SprainsSwitzerland
-
Istanbul University - CerrahpasaRecruitingForward Head PostureTurkey (Türkiye)
-
Rigshospitalet, DenmarkRecruitingHyperkalemic Periodic Paralysis | Hypokalemic Periodic ParalysisDenmark
-
University of ZululandCompletedOsteoarthritisUnited States
-
University of Colorado, DenverCompletedMultiple SclerosisUnited States
-
University of VigoNot yet recruitingBreast Cancer | Breast Cancer Survivor | Breast Cancer Patients | Breast Cancer - FemaleSpain
-
University of LisbonFundação para a Ciência e a TecnologiaActive, not recruiting
-
Asan Medical CenterRecruitingBreast NeoplasmsKorea, Republic of